---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-019426"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:53:47.913199+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma secures exclusive worldwide license for TERN-701 from Hansoh; $1M upfront

## Summary
- Amendment grants Terns exclusive, perpetual, worldwide (excl. Hansoh territory) license to Hansoh patents for TERN-701.
- Terns pays $1.0M upfront fee plus tiered royalties of 0.75%-1.25% on net sales covered by licensed patents.
- License covers TERN-701 as sole active ingredient; replaces prior non-exclusive, non-sublicensable license.
- Hansoh territory remains mainland China, Taiwan, Hong Kong, and Macau.

## SEC filing metadata
- accession: 0001193125-26-019426
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312526019426/0001193125-26-019426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312526019426/d10827d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-019426
- JSON: https://secwatch.observer/filing/0001193125-26-019426.json
- Plain text: https://secwatch.observer/filing/0001193125-26-019426.txt

## Source-grounded claims
- claim_id: c71c486d38a5c5987de8274d2fa58584158f1329
  claim: Terns Pharmaceuticals, Inc. amended Amendment to Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. and certain of its affiliates valued at $1.0 million upfront license fee (effective 2026-01-16).
  evidence_excerpt: On January 16, 2026, Terns Pharmaceuticals, Inc. (the “Company”) and its subsidiaries entered into an Amendment (the “Amendment”) to its existing Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. and certain of its affiliates (collectively, “Hansoh”), dated July 27, 2020 (the “Option and License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000119312526019426/0001193125-26-019426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.